Comparative evaluation of a novel card-based spacer (MDI PLUS®) versus traditional aerochamber plus®: In-vivo and ex-vivo bioavailability study
- PMID: 40706768
- DOI: 10.1016/j.ejps.2025.107215
Comparative evaluation of a novel card-based spacer (MDI PLUS®) versus traditional aerochamber plus®: In-vivo and ex-vivo bioavailability study
Abstract
Background: Effective aerosol delivery via pressurized metered dose inhalers (pMDIs) is often compromised by poor actuation-inhalation coordination. Spacer devices are commonly used to improve lung deposition. This study aimed to compare the lung and systemic bioavailability of salbutamol delivered via pMDI alone, with a traditional AeroChamber Plus® spacer, and with a novel disposable MDI Plus® carton spacer.
Methods: In a randomized, three-period crossover study, 20 healthy adults received 5 puffs (100 µg/puff) of salbutamol via each inhalation setup. Urine samples were collected 30 min post-inhalation (for lung bioavailability) and over 24 h (for systemic absorption). An ex-vivo setup using inhalation filters was also employed to quantify total delivered dose.
Results: The ex-vivo mean ± SD total collected dose of salbutamol was significantly higher with pMDI alone (352.35±23.41 µg) than AeroChamber Plus (196.57±13.32 µg, p < 0.001) and MDI Plus (182.86±11.34 µg, p < 0.001). Urinary salbutamol values at 30 min were significantly greater with AeroChamber Plus (14.61±4.36 µg, p < 0.001) and MDI Plus (10.97±3.83 µg, p < 0.01) compared to pMDI alone (5.92±1.07 µg). Urinary salbutamol at 24 h showed higher systemic bioavailability with pMDI alone (139.09±15.68 µg) versus when connected with both AeroChamber Plus and MDI Plus, 79.57±19.48, and 59.26±18.12 µg, p < 0.001, respectively.
Conclusion: Compared to the pMDI alone, both spacers significantly enhanced lung delivery and reduced systemic absorption. Whilst the AeroChamber Plus® delivered slightly more medication to the lung, the MDI Plus® spacer offers a cost-effective alternative that is suitable for emergencies and outdoor use.
Keywords: AeroChamber Plus spacer; MDI Plus; Metered dose inhaler; aerosolized therapy; inhaler; salbutamol, pMDI, Spacer, Aerosol delivery, Lung deposition, Respiratory diseases, Asthma care.
Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Evaluation of a cardboard-based spacer for enhancing aerosol delivery from pressurized metered dose inhalers.J Asthma. 2025 Jul;62(7):1141-1147. doi: 10.1080/02770903.2025.2463965. Epub 2025 Feb 12. J Asthma. 2025. PMID: 39907606
-
Assessment of Emergency Spacers Versus Traditional Spacers, An In-Vitro Model for Aerosol Delivery.AAPS PharmSciTech. 2025 May 16;26(5):138. doi: 10.1208/s12249-025-03136-1. AAPS PharmSciTech. 2025. PMID: 40379925
-
Balancing efficacy and portability: comparative in vitro/in vivo evaluation of MDI PLUS® versus AeroChamber2go™ spacers for aerosol delivery.J Asthma. 2025 Sep 1:1-6. doi: 10.1080/02770903.2025.2552742. Online ahead of print. J Asthma. 2025. PMID: 40888649
-
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260. Health Technol Assess. 2001. PMID: 11701099
-
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. doi: 10.3310/hta12190. Health Technol Assess. 2008. PMID: 18485271
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources